Home » Stocks » ISEE

IVERIC bio, Inc. (ISEE)

Stock Price: $8.95 USD 0.05 (0.56%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 928.87M
Revenue (ttm) n/a
Net Income (ttm) -96.27M
Shares Out 93.31M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $8.95
Previous Close $8.90
Change ($) 0.05
Change (%) 0.56%
Day's Open 9.04
Day's Range 8.51 - 9.19
Day's Volume 1,512,373
52-Week Range 3.97 - 10.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News a...

Other stocks mentioned: GTBP, NRXP
5 days ago - PennyStocks

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021.

6 days ago - Business Wire

IVERIC bio (ISEE) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

1 week ago - Zacks Investment Research

Iveric bio Inc (NASDAQ: ISEE) priced its underwritten public offering of 11.6 million shares at $8.60 per share, representing a discount of 4.6% from the last close price of $9.01 on Monday. Underwriter...

1 week ago - Benzinga

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock.

1 week ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it is commencing an underwritten public offering of shares of its common stock.

1 week ago - Business Wire

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Iveric Bio Inc (NASDAQ: ISEE) has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of the GATHER2 trial of Zimura (avacincaptad pegol) for geograp...

2 weeks ago - Benzinga

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company received written agreement from the US FDA under a Special Protocol Assessment (SPA) for the design of GATHER2.

2 weeks ago - Business Wire

Iveric Bio Inc (NASDAQ: ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) secondary t...

1 month ago - Benzinga

NEW YORK--(BUSINESS WIRE)--Iveric Bio will present data on Zimura GATHER2 and new GATHER1 post-hoc analyses at its Dry Age-Related Macular Degeneration Virtual Symposium.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium on June 18, 2021, from 10:00 a.m. to 12:00 p.m. ET.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the quarter ended March 31, 2021 and provided a general business update.

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to four newly hired, non-executive employees.

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021.

2 months ago - Business Wire

ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021

Other stocks mentioned: ARR, GMDA, LIQT, LMB
2 months ago - Zacks Investment Research

EXTN, PSXP, ISEE, OR, and QIWI have been added to the Zacks Rank #5 (Strong Sell) List on April 21, 2021

Other stocks mentioned: EXTN, OR, PSXP, QIWI
3 months ago - Zacks Investment Research

JOBS, BUD, EURN, ISEE, and KL have been added to the Zacks Rank #5 (Strong Sell) List on April 6, 2021

Other stocks mentioned: BUD, EURN, JOBS, KL
3 months ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--Iveric Bio today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years.

3 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.

6 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.

7 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company's common stock.

7 months ago - Business Wire

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.

8 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced today that the Company will participate in upcoming virtual investor conferences in November.

8 months ago - Business Wire

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long...

Other stocks mentioned: CTIC, CERC, LGND
8 months ago - Insider Monkey

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020.

8 months ago - Business Wire

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.

10 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted two newly hired, non-executive employees a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.

10 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.

10 months ago - Business Wire

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.

11 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.

11 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.

11 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced the election of Mark S. Blumenkranz, M.D.

1 year ago - Business Wire

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: RUBY, ZYNE
1 year ago - Seeking Alpha

Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News

1 year ago - Seeking Alpha

An upsized public offering has investors increasingly confident about its prospects.

1 year ago - The Motley Fool

Shares of New York-based biopharma IVERIC bio Inc (NASDAQ: ISEE) were advancing strongly Monday morning on the back of a positive clinical readout.

1 year ago - Benzinga

NEW YORK, June 15, 2020 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura® (avacincaptad pego...

1 year ago - PRNewsWire

IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 13th

Other stocks mentioned: IDCC, MRSN, SLDB
1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 12th

Other stocks mentioned: CHGG, CLLS, HEAR
1 year ago - Zacks Investment Research

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ISEE

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
David Guyer
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
ISEE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IVERIC bio stock is "Strong Buy." The 12-month stock price forecast is 15.33, which is an increase of 71.28% from the latest price.

Price Target
$15.33
(71.28% upside)
Analyst Consensus: Strong Buy